compounded semaglutide safety risks FDA alerts health care providers, compounders and patients of dosing errors associated with injectable products FDA is moving to restrict

Spending on GLP-1 drugs in Medicare Part D skyrocketed over the past several years, according to a new analysis from KFF

The full conversion table is in the reconstitution section

Semaglutide is contraindicated with a personal or family history of MEN2 or medullary thyroid carcinoma (MTC) Semaglutide may interact with certain medications, so it is important to disclose all the medications you are taking, including over-the-counter drugs and supplements

A practical maintenance checklist for the stopping period Common reasons people stop GLP-1 medications and what to consider in each case Cost and insurance coverage Access and cost remain the most common reasons people stop GLP-1 medications in the real world

Browse more options in our GLP-1 Metabolic Support collection

This analysis is a follow-up to research presented by Prime/MRx in 2023, which found that 71 percent of individuals were no longer taking these drugs for weight loss at one year, representing a further 14 percent point decrease in persistence in just one year